| Market Cap | ₹57,202 CrMid-range Performer |
|---|---|
| TTM Revenue | ₹17,321 CrOperating Revenue |
| P/E TTM | 115.49xSector PE 45.9x |
| Day RSI | 28.28Oversold Zone |
| Order from | Genentech |
Key highlights
- European Union and UK commercial launch for Pebrilzo scheduled for Q1 calendar year 2027
- United States market entry secured for Q3 calendar year 2028
- Rest of World (RoW) launches planned between 2026 and 2028 with potential for earlier entry
- Global settlement resolves all pending disputes with Genentech regarding the reference product Perjeta
- Pebrilzo targets HER2-positive breast cancer by inhibiting the proliferation of specific tumor cells
Strategic Resolution of Global Patent Disputes
Biocon Limited and Genentech have executed a comprehensive patent settlement agreement to resolve all pending legal disputes between the two companies. This agreement spans multiple jurisdictions, specifically naming the U.S. and Canada, and provides Biocon with the necessary licenses to launch Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab).
Pebrilzo is a monoclonal antibody that binds with high affinity to the human epidermal growth factor receptor 2 (HER2), used in treating HER2-positive breast cancer across various disease stages. The settlement allows Biocon to focus on commercial execution without the overhang of litigation costs or market entry uncertainty.
Phased Commercial Launch Timelines
- European Union & UK: Licensed launch set for Q1 of calendar year 2027
- United States: Commercial market entry secured for Q3 of calendar year 2028
- Rest of World: Phased rollout scheduled across 2026-2028 depending on jurisdiction
- Regulatory Contingency: All regional product launches remain subject to final regulatory approvals
- Confidentiality: Specific financial terms and secondary conditions of the agreement remain undisclosed
Contextualizing Biocon's Biosimilar Pipeline Strategy
The Genentech settlement follows a pattern of strategic intellectual property resolutions for Biocon. In December 2025, the company reached a similar global settlement with Regeneron and Bayer for the commercialization of its biosimilar Aflibercept (Yesafili). More recently, in September 2026, Biocon secured a 10-year partnership in Brazil under the PDP program for Pertuzumab supply, covering approximately 70% of that nation's public market demand.
These agreements reinforce Biocon's strategy of securing long-term market access through legal settlements and government partnerships, ensuring a predictable revenue runway for its complex biologics portfolio as it moves toward H2 FY27 expansion targets.
Financial Performance and Market Dynamics
In the quarter ended June 30, 2026, Biocon reported a net profit of ₹141.1 crore, representing a 349.4% year-on-year growth despite a 4% sequential revenue decline to ₹4,336 crore. The company maintains an operating profit margin of 19.54%, which is slightly above the 19.0% recorded four quarters prior. Management previously guided for revenue acceleration and margin expansion in the second half of FY27, aided by a projected ₹300 crore reduction in annual interest expenses following balance sheet deleveraging.
Currently, the stock's RSI of 28.28 indicates it is in technically oversold territory as it trades at a P/E of 115.49x, compared to the biotechnology industry average of 99.27x.
| Date | Announcement | Amount |
|---|---|---|
| 08 Sep 2026 | Partnership agreement with Bahiafarma and Bionovis for 10-year Pertuzumab supply under Brazil's PDP programSource: biocon.com | – |
| 20 Jan 2026 | Subsidiary Syngene International extended strategic research collaboration with Bristol Myers Squibb through 2035Source: prnewswire.com | – |
| 23 Dec 2025 | Out-licensing agreement with Ajanta Pharma to market Semaglutide across 26 countries in Africa, the Middle East, and Central AsiaSource: biocon.com | – |
| 23 Dec 2025 | Expanded in-licensing agreement with Fujifilm Kyowa Kirin Biologics for exclusive global manufacturing and commercialization rights to biosimilar Adalimumab (Hulio)Source: biocon.com | – |
| 13 Dec 2025 | Global settlement and license agreement with Regeneron and Bayer to commercialize biosimilar Aflibercept (Yesafili)Source: newsmantra.in | – |
| 16 Oct 2025 | Expanded partnership agreement with Civica to commercialize private-label Insulin Glargine in the U.S.Source: biocon.com | – |
What to watch next
- Announcement of Q2 FY27 consolidated financial results scheduled for November 5, 2026
- Scheduled U.S. commercial market entry for interchangeable biosimilar Aflibercept (Yesafili) in H2 CY2026
- Commencement of the 10-year Pertuzumab supply agreement with Bahiafarma and Bionovis in Brazil
| Share price | ₹351 |
|---|---|
| Market capitalisation | ₹57,202.26 Cr |
| Revenue (annual) | ₹16,927.00 Cr |
| Net profit (annual) | ₹385.60 Cr |
| Revenue (latest quarter) | ₹4,336.00 Cr-4.00% vs previous quarter |
| Net profit (latest quarter) | ₹141.10 Cr+12.07% vs previous quarter |
| P/E (TTM) | 115.49×Sector 45.9× |
| Promoter holding | 44.68%-0.23% QoQ |
| FII holding | 8.14%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Biocon Limited announcing a global patent settlement and license agreement with Genentech for Pebrilzo. Market figures from a third-party data provider.
Track Biocon live
Get the next Biocon filing on Telegram seconds after it lands. 15 days free.
